March Madness is here, or so they say on the basketball courts. But Marchs madness is slowly moving off to more than just the courts. This Bullish Momentum has slowly found this growing company. But this article isn't about that they did, but where they are truly going, and how March Madness came to play. Our starting lineup will begin on March 25th. Julie Brown, the Chief Financial Officer, will be participating in a virtual fireside chat at the BNP, or known as The Paribas Exane Healthcare Conference on that Tuesday evening. On this same very special day, GSK will also be heading in front of the FDA for their final regulatorry decision. Next David Redfern, President of Corporate Development will be attending the Goldman Sachs Biopharma Innovation Summit in London on this lucky Thursday. Now their starting lineup for the day begins with a morning Star rating at 58 dollars per share. Currently 20 dollars higher then the current share value. GSK is also completely jg off a 7 day stretch, showing that this company is becoming the popular investor choice. Now GSK is holding 71 assets in their individual pipeline , 19 assets in phase 3, and have announced this year they should have 5 major products approved by the FDA. Taking a look at all of this, with their Earnings two weeks away, this starting lineup is starting to seem like the last dream team to take the courts.
How well do narratives help inform your perspective?
Disclaimer
The user DailyInvestors has a position in LSE:GSK. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
